Topical 3% Diclofenac in 2.5% Hyaluronan Gel for the Treatment of Actinic Keratoses

Skin Therapy Letter-Family Practice Edition

关键词: actinic keratoses;    diclofenac;    hyaluronic acid Actinic Keratoses (AKs) are a relatively common premalignant inflammatory skin lesion;    which affect a large proportion of individuals with light skin that has been exposed to sun and/or artificial UV radiation. Over a period of 10 years;    a person with 8 AKs has a 6.1-10.2% chance of developing a squamous cell carcinoma.1 Risk factors for AKs include being:• fair skinned• male• >50 years of age• sensitive to the sun with poor ability to tan and frequent sunburns• on a high fat diet• immunosuppressed.2-6AKs have a wide range of clinical presentations and there is no single therapy that treats the complete spectrum of pathologies and individuals. Current treatment options include cryosurgery;    curettage;    surgical excision;    laser;    chemical peels;    photodynamic therapy (PDT);    topical fluorouracil;    and retinoids. Topical imiquimod has also been used experimentally.7 However;    all these options have been associated with local discomfort and pain in some cases.8;    9 Topical 3% diclofenac in 2.5% hyaluronic acid (Solaraze®;    Bioglan Pharma) is a new treatment for AKs that has been approved in the US;    Canada and several countries in the European Union.;   

DOI  :  

学科分类：医学（综合）

来源: Skin Therapy Letter-Family Practice Edition

【 摘 要 】

Actinic Keratoses (AKs) are epidermal skin lesions that have the potential to develop into squamous cell carcinoma. Many of the treatment options available can cause discomfort, pain or skin irritation. Topical 3% diclofenac in 2.5% hyaluronan gel (Solaraze™, Bioglan Pharma) is a relatively new treatment that has been shown to be effective and well tolerated for the treatment of AKs.

【 授权许可】

Unknown